Adjusted EBITDA: $7.2 million for the third quarter.Net Profit: $3 million or $0.06 per share for the quarter.Revenue Growth: 8% increase from the same period…
October 11, 2024
October 10, 2024
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
Femasys Inc.Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member CouncilATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY),…
Immutep LimitedMedia ReleaseSYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing…